News

Visual effects reported from first human artificial retina

Nano Retina has announced preliminary results for first-in-human implantation of its NR600 artificial retina device. The first two patients to receive the device in March 2020 reported visual effect. The NR600 mimics the natural physiological processes of the human eye and restores functional vision to persons blinded by retinal degenerative diseases, including age-related macular degeneration [Read More]

Where Are We Now?

A Summary of a Quarter-Century of Low Vision Research and Development Presented to the International Low Vision Support Groupby Dan Roberts, Director Macular Degeneration Support, the charitable parent corporation of our International Low Vision Support Group, is celebrating its 25th year as a leading resource for people affected by macular degeneration and similar diseases leading [Read More]

NIH researchers discover tooth-enamel protein in eyes with dry AMD

Information from the National Eye Institute A protein that normally deposits mineralized calcium in tooth enamel may also be responsible for calcium deposits in the back of the eye in people with dry age-related macular degeneration (AMD), according to a study from researchers at the National Eye Institute (NEI). This protein, amelotin, may turn out [Read More]

Beovu Safety Under Investigation

Patients who are undergoing anti-VEGF treatment with Beovu (brolucizumab) for wet AMD should be aware that the drug is currently being investigated by the drug’s manufacturer, Novartis, for potential adverse events in some patients.  Beovu was approved for clinical use in October 2019, and it has since shown to be an effective and long-lasting inhibitor [Read More]

Some Wet AMD Patients May Not Need Injections Forever

A study concluded in 2019 suggests that some patients with wet AMD can retain good visual acuity with no treatment for at least 3 years after stopping anti-VEGF treatment. Researchers compared two groups from the 2008-2009 Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). The first group was comprised of patients who had been released [Read More]